# Drug/Drug Interactions in the Elderly

Bruce G. Pollock, M.D., Ph.D.

- Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following:
- A. Similar
- B. Twice as great
- C. Greater than 5 x as frequent
- D. Greater than 10 x as frequent

- Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes?
- A. 1A2
- B. 2D6
- C. 3A4
- D. All of the above

- Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate?
- A. Ketoconazole
- B. Erythromycin
- C. Calcium antagonists
- D. Any of the above

- Which of the following medications has anticholinergic properties?
- A. Furosemide
- B. Warfarin
- C. Ranitidine
- D. Digoxin
- E. All the above

- The risk of drug/drug interactions is increased by which of the following?
- A. Narrow therapeutic index of co-administered agent
- B. Highly potent co-administered enzyme inducer or inhibitor
- C. Greater sensitivity to adverse effects in elderly patients
- D. Co-administration of multiple drugs
- E. All the above


# **Major Teaching Points**

- Elderly patients are highly vulnerable to drug/drug interactions
- Two important types of drug/drug interactions to understand and prevent are:
  - Pharmacokinetic interactions based on drug metabolism through the cytochrome P450 system
  - Pharmacodynamic interactions based on additive serum anticholinergicity

# **Brief Outline**

- Adverse drug interactions' relationship to age, location, number of prescribed drugs
- Cytochrome P450 drug interactions
- Drug interactions based on additive serum anticholinergicity
- Coping with drug/drug interactions
   Suggested readings


#### Adverse Drug Reactions (ADRs) as a Function of Increasing Age



## Adverse Drug Reactions in the Nursing Home

Sychoactive medications (antipsychotics, antidepressants, and sedatives/hypnotics) and anticoagulants were the medications most often associated with preventable ADRs

#### Relationship Between Prescribing Rate and Prevalence of Potential Drug Interactions




Nolan L, O'Malley K. Age Ageing. 1989;18:52-56.

11

# **Clinical Dilemma**

- Number of possible drug interactions too large to memorize
- Difficult to determine which interactions are important
- Conflicting promotional claims

# Cytochrome P-450 Enzyme Subtypes



Representative substrates
Caffeine, theophylline, tacrine
Propofol, bupropion
Phenytoin, S-warfarin, tolbutamide, NSAIDs
Omeprazole (partial contributor to many)
Some CNS and cardiac drugs
Fluranes, chlorzoxane
(many)

# <u>CYP3A</u>

- High abundance
- Present in G.I Tract
- No polymorphism, but high individual variability

# **CYP3A Substrates**

Complete	Partial
Benzodiazepines (short t <sub>1/2</sub> )	Zolpidem
Buspirone	Amitriptyline
Trazodone	Imipramine
Nefazodone	Sertraline
Cyclosporine	Citalopram
Statins	Diazepam
Calcium antagonists	Clozapine
Quinidine	
Protease Inhibitors	
Sildenafil	

# **CY3A Inhibitors**

High Risk	Moderate Risk
Ketoconazole	Fluconazole
Itraconazole	Fluvoxamine
Nefazodone	Fluoxetine
Ritonavir (acute)	Grapefruit juice
Erythromycin	Other HIV PIs
Clarithromycin	Delavirdine
Calcium Antagonists	Cimetidine


# **CYP3A Inducers**

#### **\***Rifampin

- Barbiturates
- Carbamazepine
- Ritonavir (chronic)
- \* Nevirapine

Hypericum perforatum (St. John's Wort)


#### **CYP3A4: Verapamil**




Racemic verapamil clearance data are plotted versus age for women (*solid circles*) and men (*open circles*). The *solid line* represents the regression of clearance versus age relationship in women (P < .004) and the *broken line* represents the regression of clearance versus age in men (regression not significant).

Schwartz JB, et al. Clin Pharmacol Ther. 1994;55:509-517.

# St. John's Wort



#### CYP1A2 Phenotyping (Caffeine) Results Before and After Estrogen Treatment of Healthy Postmenopausal Women



Pollock BG, et al. J Clin Psychopharmacol. 2000;20:137-140.

#### <u>Cytochrome P-450:</u> Enzymes and Selected Substrates

1A2	2C	2D6	3A4
Theophylline	Phenytoin	Codeine	Antihistamines
Warfarin	Warfarin	Venlafaxine	Calcium channel blockers
Antipsychotics	Amitriptyline	Trazodone	Carbamazepine
Benzodiazepines	Clomipramine	Risperidone	Cisapride
Fluvoxamine	Omeprazole	Haloperidol	Corticosteroids
		Tramadol	Cyclosporine
		β-Blockers	Fentanyl
			Protease inhibitors
			Statins
			Triazolo- benzodiazepines

Michalets EL. *Pharmacotherapy*. 1998;18:84 -112. Cupp MJ, Tracy TS. *Am Fam Physician*. 1998;57:107-116.

#### Inhibition of Human Cytochrome P-450 Isoenzymes by Newer Antidepressants

#### Cytochrome P-450 Isoenzyme

Antidepressant	1A2	2C9	2C19	2D6	2E1	3A
Fluoxetine	nik karas (* + nike	1	+ to ++	+++		SHAP.
Norfluoxetine	+ + + + + + + + + + + + + + + + + + +	++	+ to ++	+++	19 <del>- 1</del> 9 - 19	++
Sertraline	540-000 <b>+</b> 3540	+	+ to ++	+		+
Desmethylsertraline	1	+	+ to ++	+		+
Paroxetine	Sal Street	+	The the	+++	75 12	+
Fluvoxamine	+++	++	+++	33 <b>+</b> 33		++
Citalopram	ter ser ter ter ter ter ter ter ter ter ter t	0	0	0	0	0
R-Desmethylcitalopram	0	0	0	+	0	0
Escitalopram	0	0	0	0	0	0
S-Desmethylcitalopram	0	0	0	0	0	0
Nefazodone	0	0	0	0		+++
Triazoledione	0	0	0	0	9 (c <del>. 4</del> 9 (c)	10 to (+).
Hydroxynefazodone	117 <b>O</b>	0	0	0	$R_{\rm eff} \rightarrow 0$	+++
Venlafaxine	0	0	0	0		0
O-Desmethylvenlafaxine	0	0	0	0		0
Mirtazapine	0			+	1.3. <u></u>	0


0 = minimal or zero inhibition.

- + = mild inhibition.
- ++ = moderate inhibition.
- +++ = strong inhibition.

= no data available.

Greenblatt DJ, et al. *J Clin Psychiatry*. 1998;59(suppl 15):19-27. von Moltke LL, et al. *Drug Metab Disposition*. 2001;29:1102-1108.

### Incidence of Bleeding During Anticoagulant Therapy



Beyth RJ, Schorr RI. Drugs Aging. 1999;14:231-239.

#### American Medical Directors Association "Top 10" Drug Interactions Includes:

# Warfarin with:

NSAIDs Macrolides Phenytoin Sulfa Drugs Quinolones


# Warfarin Metabolism

**Fluoxetine** S-warfarin CYP2C9 **Fluvoxamine** (Sertraline) (Paroxetine) **Fluvoxamine R**-warfarin CYP1A2 (major pathway) (Fluoxetine) (Sertraline) (Paroxetine)



*R*-warfarin CYP2C19 (minor pathway) & CYP3A4

#### Platelet Activation in Depressed Patients With Ischemic Heart Disease After Paroxetine or Nortriptyline Treatment



 Effect of paroxetine ( ) and nortriptyline () on PF4 plasma levels in depressed patients with ischemic heart disease. Data presented are mean ± SEM

\**P* < .05 versus baseline levels. PF4 = platelet factor 4. Pollock BG, et al. *J Clin Psychopharmacol.* 2000;20:137-140.

## Anticholinergic Medications Commonly Prescribed in the Elderly

#### **Commonly Prescribed in the Elderly**

- Furosemide
- \* Digoxin
- Theophylline
- Warfarin
- Prednisolone
- Triamterene and hydrochlorothiazide

- Nifedipine
- \* Isosorbide
- \* Codeine
- Cimetidine
- Captopril
- \* Ranitidine
- Dipyridamole

#### Age, Sex, Education, Number of Medications, <u>MMSE score, and SA (N = 201)</u>

Mean (SD) Age	78.2 (5.2)
Female (N, %)	122 (60.7%)
Education (< high school)	38.3 %
Number of Medications	5.2 (3.4)
Number of Anticholinergic Medications	0.91 (1.23)
MMSE	26.8 (3.5)
SA (pmol/mL) — Mean (SD)	1.45 (1.10)
Median (Range)	1.25 [0-5.70]

#### MMSE = Mini-Mental State Examination.

SA = serum anticholinergicity.

Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58.

### Logistic Regressions: SA as a Continuous Variable

		OR	95% CI
Age		1.20	(1.09, 1.32)
Sex	Male	1.00	
	Female	1.15	(0.37, 3.57)
Education	< high school	1.00	
	≥ high school	0.39	(0.13,1.21)
# of Rx	0-3	1.00	
	* 4-6 🔅	1.46	(0.39,5.44)
	> 6	1.21	(0.29,5.05)
SA		16.71	(2.02, 138.29)

#### SA = serum anticholinergicity.

Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58.

# Elderly Are More Difficult to Treat Safely

- Pharmacokinetic changes result in higher and more variable drug concentrations
- The elderly often take multiple medications
- Greater sensitivity exists to a given drug concentration
- Homeostatic reserve may be impaired

#### **When To Worry About Drug Interactions**

Narrow therapeutic index of victim
Highly potent inducer or inhibitor

# **Coping With Drug Interactions**

Anticipation and prevention
 Highly potent inducer/inhibitor
 Narrow therapeutic index of victim
 Victims dependent on one metabolic enzyme/transport protein

# **Coping With Drug Interactions**

- Recognize interaction potential of "nondrugs" (herbals)
- Keep knowledge base current
- Consider interactions whenever the clinical picture unexpectedly changes

# **Suggested Readings**

- Pollock BG: Geriatric Psychiatry: Psychopharmacology: General Principles. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VII. Baltimore: Williams & Wilkins 2000 pp 3086-3090.
- DeVane CL, Pollock BG: Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry 60[suppl 20]:38-44, 1999.

- Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following:
- A. Similar
- B. Twice as great
- C. Greater than 5 x as frequent
- D. Greater than 10 x as frequent

- Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes?
- A. 1A2
- B. 2D6
- C. 3A4
- D. All of the above

- Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate?
- A. Ketoconazole
- B. Erythromycin
- C. Calcium antagonists
- D. Any of the above

- Which of the following medications has anticholinergic properties?
- A. Furosemide
- B. Warfarin
- C. Ranitidine
- D. Digoxin
- E. All the above

- The risk of drug/drug interactions is increased by which of the following?
- A. Narrow therapeutic index of co-administered agent
- B. Highly potent co-administered enzyme inducer or inhibitor
- C. Greater sensitivity to adverse effects in elderly patients
- D. Co-administration of multiple drugs
- E. All the above

# Self Assessment Question Answers

◆ 1. C
◆ 2. D
◆ 3. D
◆ 4. E
◆ 5. E